Javier Pinilla-ibarz
Researcher
Deparment of Immunology
Moffitt Cancer Center
United States of America
Biography
Dr. Javier Pinilla-Ibarz is affiliated to Deparment of Immunology, Moffitt Cancer Center. Dr. Javier Pinilla-Ibarz is currently providing services as Researcher. Dr. Javier Pinilla-Ibarz has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. Javier Pinilla-Ibarz contributions have acclaimed recognition from honourable subject experts around the world. Dr. Javier Pinilla-Ibarz is actively associated with different societies and academies. Dr. Javier Pinilla-Ibarz academic career is decorated with several reputed awards and funding. Dr. Javier Pinilla-Ibarz research interests include chronic leukemias with special interest in chronic myeloid leukemia and chronic lymphoid leukemias.
Research Interest
Chronic leukemias with special interest in chronic myeloid leukemia and chronic lymphoid leukemias
Publications
-
Woods DM, Woan KV, Cheng F, Sodré AL, Wang D, Wu Y, Wang Z, Chen J, Powers J, Pinilla-Ibarz J, Yu Y, Zhang Y, Wu X, Zheng X, Weber J, Hancock W, Seto E, Villagra A, Yu XZ, Sotomayor EM. T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood. 2017 Jul;130(2):146-155.
-
Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Jun;1-10.Â
-
Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 Mar;102(3):519-528.Â
